Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 15/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL94382 | 0.96 | MCHR1 (0.52) | MCHR1HTR7 | |
| SCHEMBL15891557 | 0.81 | MCHR1 (0.52) | MCHR1 | |
| SCHEMBL94417 | 0.80 | MCHR1 (0.51) | MCHR1MEN1KMT2AHTR7 | |
| SCHEMBL17233475 | 0.78 | MCHR1 (0.48) | MCHR1 | |
| SCHEMBL15891558 | 0.77 | MCHR1 (0.52) | MCHR1 | |
| SCHEMBL94521 | 0.76 | MCHR1 (0.52) | MCHR1MEN1KMT2AHTR7 | |
| SCHEMBL94555 | 0.76 | MCHR1 (0.52) | MCHR1 | |
| SCHEMBL17233536 | 0.76 | MCHR1 (0.46) | MCHR1 | |
| SCHEMBL94277 | 0.75 | MCHR1 (0.52) | MCHR1MEN1KMT2AHTR7 | |
| SCHEMBL133185 | 0.73 | MCHR1 (0.53) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618299-B2 | Azinone-substituted azapolycycle MCH-1 antagonists, methods of making, and use thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120058940-A9 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003738-A1 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MCHR1 1/4885MEN1 789/4885KMT2A 1056/4885 |
| US-20120058940-A9 | AZINONE-SUBSTITUTED AZAPOLYCYCLE MCH-1 ANTAGONISTS, METHODS OF MAKING, AND USE THEREOF | MCHR1, MCHR2, TAAR1 | MCHR1 1/4885MEN1 789/4885KMT2A 1056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.